Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8 associated disorders
View Patent ↗The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
1. A method for increasing muscle mass in a mammal comprising administering a therapeutically effective amount of an antibody selected from the group consisting of:
(a) an isolated antibody capable of binding GDF-8 comprising a heavy chain variable region comprising three complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, and a light chain variable region comprising three CDRs comprising the amino acid sequences of SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; and
(b) an isolated antibody capable of binding GDF-8 comprising the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15,
thereby increasing muscle mass in the mammal.
2. A method for treating or ameliorating amyotrophic lateral sclerosis (ALS) in a mammal comprising administering a therapeutically effective amount of an antibody selected from the group consisting of:
(a) an isolated antibody capable of binding GDF-8 comprising a heavy chain variable region comprising three complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, and a light chain variable region comprising three CDRs comprising the amino acid sequences of SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; and
(b) an isolated antibody capable of binding GDF-8 comprising the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15
thereby treating or ameliorating ALS in a mammal.
3. The method of any of claims 1 - 2 , wherein said heavy chain variable region comprises a CDR 1 comprising the amino acid sequence of SEQ ID NO: 10, a CDR 2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR 3 comprising the amino acid sequence of SEQ ID NO: 12, and said light chain variable region comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15.
4. The method of claim 3 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 3, and the amino acid sequence of SEQ ID NO:7, and a light chain variable region comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 5, and the amino acid sequence of SEQ ID NO: 9.
5. The method of claim 4 , wherein the antibody is selected from the group consisting of:
a) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9;
b) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5;
c) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5; and
d) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.
6. The method of any of claims 1 - 2 , wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.
7. The method of any of claims 1 - 2 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.
8. The method of any of claims 1 - 2 , wherein the antibody is a monoclonal antibody.
9. The method of any of claims 1 - 2 , wherein the antibody is a humanized monoclonal antibody.
10. The method of claim 3 , wherein the antibody is a monoclonal antibody or a humanized monoclonal antibody.
11. The method of claim 4 , wherein the antibody is a monoclonal antibody or a humanized monoclonal antibody.
12. The method of claim 5 , wherein the antibody is a monoclonal antibody or a humanized monoclonal antibody.
13. The method of claim 6 , wherein the antibody is a monoclonal antibody or a humanized monoclonal antibody.
14. The method of claim 7 , wherein the antibody is a monoclonal antibody or a humanized monoclonal antibody.